Glaukos — Q3 2026 Earnings Presentation

7 slides from Glaukos's earnings presentation, Oct 28, 2026

Slide 1: Glaukos: Transforming Vision. We'll Go First
GLAUKOS TRANSFORMING VISION. WE’LL GO FIRST Innovation is at the core of everything we do. At Glaukos, we push the limits of science and technology to solve unmet needs in chronic eye diseases.
Slide 2: Franchise Revenue Performance
Franchise Revenue Performance
Slide 3: 3Q 2026 Revenue Mix
3Q 2026 Revenue Mix Corneal Health $59.0M U.S. Glaucoma $118.6M International Glaucoma $33.4M
Slide 4: Keratoconus awareness campaign and CMS proposed rules for 2027
o Launched Could it be KC? disease awareness and educational campaign in partnership with NBA champion Stephen Curry to raise awareness, educate patients and families, and promote earlier detection and diagnosis o Advancing targeted marketing and DTC campaigns designed to significantly enhance aware
Slide 5: Ocular Hypertension and Open-Angle Glaucoma, Keratoconus, Blepharitis, Myopia
Ocular Hypertension and Open-Angle Glaucoma _Keratoconus Blepharitis ae Myopia——_—!
Slide 6: Product and Patient Status
PRODUCT PATIENT STATUS Mild-to-Moderate Glaucoma with Cataract FDA Approved (2012, 2018, 2020) Glaucoma (failed on prior therapy) FDA Cleared (2022} Glaucoma (label expansion) Active PMA Study / EU MDR Cert (2025) Advanced-Refractory Glaucoma QUS Approved / US Active IDE Study Ocular Hypertension -
Slide 7: Additional Information
Additional Information